Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis

Acta Neurol Belg. 2024 Feb;124(1):303-306. doi: 10.1007/s13760-023-02303-0. Epub 2023 Jun 10.

Hussein Algahtani^{1

2}, Bader Shirah³, Abdulhadi Alqahtani⁴, Nawal Abdelghaffar^{5

6}, Samiah Makki⁷

¹ Department of Medicine, Aseer Central Hospital, Abha, Saudi Arabia. halgahtani@hotmail.com.
² Neurology Section, Department of Medicine, King Abdulaziz Medical City, P.O. Box: 12723, Jeddah, 21483, Saudi Arabia. halgahtani@hotmail.com.
³ Department of Neuroscience, King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia.
⁴ College of Medicine, King Khalid University, Abha, Saudi Arabia.
⁵ Department of Medicine, Aseer Central Hospital, Abha, Saudi Arabia.
⁶ Neurology Department, Kasr Al Ainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.
⁷ College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

No abstract available

Keywords: Half-dose; Multiple sclerosis; Ocrelizumab; Personalized.

Publication types